MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/00048674221077619

Медицинская библиотека · The Australian and New Zealand journal of psychiatry · 2022

Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes.

Köhler-Forsberg Ole, Sylvia Louisa G, Thase Michael, Calabrese Joseph R, Tohen Mauricio, Bowden Charles L, McInnis Melvin, Iosifescu Dan V, Kocsis James H, Friedman Edward S, Ketter Terence A, McElroy Susan L, Shelton Richard C, Fung Vicki, Ostacher Michael J, Nierenberg Andrew A

Рандомизированное исследованиеСтатьяПеревод в очереди

Аннотация

OBJECTIVE

Patients with bipolar disorder treated with lithium often require additional antipsychotics or anticonvulsants. However, the comparative effectiveness and safety of these agents as add-on to lithium has not been studied.

METHODS

This secondary analysis combined two similar 24-week trials on outpatients with bipolar disorder randomized to lithium (target serum level 0.4-0.6 mEq/L). Guideline-based adjunctive antipsychotics (Li+AP) and anticonvulsants (Li+AC) could be used if clinically indicated and was assessed at every study visit. Response was measured on the Clinical Global Impression scale and we performed adjusted mixed effects linear regression analyses. Analysis of variance tests compared metabolic measures including a binary diagnosis of metabolic syndrome before and after 24 weeks of treatment.

RESULTS

Among 379 outpatients (57% female, mean age 38 years, mean Clinical Global Impression 4.4), users of Li+AP (N = 50, primarily quetiapine and aripiprazole) improved to a similar degree (mean Clinical Global Impression improvement = 1.6, standard deviation = 1.5) as those using lithium-only (i.e. without adjunctive antipsychotics or anticonvulsants, N = 149, mean Clinical Global Impression improvement = 1.7, standard deviation = 1.4) (p = 0.59). Users of Li+AC (N = 107, primarily lamotrigine and valproate, mean Clinical Global Impression improvement = 1.2, standard deviation = 1.3) and users of Li+AP+AC (N = 73, mean Clinical Global Impression improvement = 1.1, standard deviation = 1.3) showed worse response compared to lithium-only users (all p < 0.01). When comparing Li+AP to Li+AC, users of Li+AP improved slightly better on general (p = 0.05) and manic symptoms (p = 0.01), but showed a worse development of glucose, triglycerides, and metabolic syndrome.

CONCLUSION

Despite treatment-by-indication confounding, these findings are relevant for real-world treatment settings and emphasize the need for randomized trials on this clinically important topic.

Для цитирования: Köhler-Forsberg Ole, Sylvia Louisa G, Thase Michael, Calabrese Joseph R, Tohen Mauricio, Bowden Charles L, McInnis Melvin, Iosifescu Dan V, Kocsis James H, Friedman Edward S, Ketter Terence A, McElroy Susan L, Shelton Richard C, Fung Vicki, Ostacher Michael J, Nierenberg Andrew A. Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes.. The Australian and New Zealand journal of psychiatry. 2022. DOI: 10.1177/00048674221077619.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.